GlassScriptPhysician profile
Heather Gonzalez
NPI 1740683481
$2,703.62
in general payments reported to CMS, 2019-2025
26 companies · $19.01 in 2025
The $19.01 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $976 · 2022: $934 · 2023: $759 · 2024: $15.88 · 2025: $19.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $347.69 | 2021-2023 | Rexulti |
| Novo Nordisk INC | $301.00 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $257.01 | 2021-2023 | Freestyle Libre 3 |
| Abbvie INC. | $252.69 | 2021-2023 | |
| Daiichi Sankyo INC. | $224.93 | 2021-2023 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $180.79 | 2021-2022 | |
| Esperion Therapeutics, INC. | $140.94 | 2021-2023 | Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $138.54 | 2022 | |
| Sumitomo Pharma America, INC. | $129.12 | 2023 | Gemtesa |
| Lilly USA, LLC | $109.25 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $93.79 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.08 | 2021-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $78.88 | 2021 | |
| Pfizer INC. | $78.77 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.13 | 2022-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42.38 | 2022 | |
| Scilex Pharmaceuticals INC. | $29.37 | 2022-2023 | Ztlido |
| Dexcom, INC. | $27.29 | 2021 | |
| Evoke Pharma, INC. | $23.82 | 2023 | Gimoti |
| Amneal Pharmaceuticals LLC | $23.41 | 2022 | |
| Exact Sciences Corporation | $19.01 | 2025 | The Cologuard Plus Collection Kit |
| Medtronic, INC. | $15.88 | 2024 | Venaseal |
| Grt US Holding, INC. | $15.34 | 2022 | |
| Nestle Healthcare Nutrition INC. | $14.04 | 2023 | |
| Evofem Biosciences, INC. | $13.24 | 2022 | |
| Hikma Pharmaceuticals USA | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.